GlassScriptPhysician profile
Janiene Luke
NPI 1700048634
$101,685.68
in general payments reported to CMS, 2019-2025
13 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $99.00 · 2022: $19K · 2023: $40K · 2024: $42K · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $12K · Travel and Lodging: $2,828 · Food and Beverage: $2,036 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,866.00 |
| Consulting Fee | $12,190.00 |
| Travel and Lodging | $2,827.58 |
| Food and Beverage | $2,035.64 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51,239.46 | 2022-2024 | Olumiant, Taltz |
| Genzyme Corporation | $24,331.58 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $15,412.11 | 2023-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $9,671.84 | 2024 | Zoryve |
| Allergan, INC. | $246.02 | 2019-2022 | |
| Pfizer INC. | $237.90 | 2022-2025 | |
| Ucb, INC. | $160.23 | 2022 | |
| Abbvie INC. | $118.20 | 2019 | |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.95 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $37.81 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $20.60 | 2025 | Sotyktu |
| Boston Scientific Corporation | $16.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janiene Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.